Comparative Pharmacology
Head-to-head clinical analysis: ANISOTROPINE METHYLBROMIDE versus DICYCLOMINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANISOTROPINE METHYLBROMIDE versus DICYCLOMINE HYDROCHLORIDE.
ANISOTROPINE METHYLBROMIDE vs DICYCLOMINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Anisotropine methylbromide is a quaternary ammonium anticholinergic agent that competitively antagonizes acetylcholine at muscarinic receptors (M1, M2, M3), thereby inhibiting parasympathetic nerve impulses. This leads to relaxation of smooth muscle in the gastrointestinal tract, decreased gastric acid secretion, and reduced motility.
Competitive antagonist of muscarinic acetylcholine receptors, inhibiting parasympathetic nerve impulses in the gastrointestinal tract, leading to smooth muscle relaxation.
Adult: 1-2 mg intramuscularly or subcutaneously every 4-6 hours as needed. Maximum: 8 mg/day.
10-20 mg orally 3-4 times daily
None Documented
None Documented
Clinical Note
moderateAnisotropine methylbromide + Fesoterodine
"The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Fesoterodine."
Clinical Note
moderateAnisotropine methylbromide + Quinidine
"The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Quinidine."
Clinical Note
moderateAnisotropine methylbromide + Topiramate
"The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Topiramate."
Clinical Note
moderateTerminal elimination half-life is approximately 1.5-2.0 hours in patients with normal renal function; prolonged in renal impairment (up to 8-10 hours).
1.8 to 2.5 hours (terminal half-life, shorter in younger patients)
Primarily renal (approx. 70-80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal excretion accounts for 20-30%, mainly as metabolites.
Renal (∼79.5% as unchanged drug and metabolites) with minor biliary/fecal elimination (∼8-10%)
Category C
Category A/B
Anticholinergic
Anticholinergic
Anisotropine methylbromide + Methadone
"The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Methadone."